Literature DB >> 1335638

Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine.

P Goubau1, V Van Gerven, A Safary, A Delem, J Knops, E D'Hondt, F E André, J Desmyter.   

Abstract

A randomized double-blind comparison of five killed hepatitis A vaccine preparations was carried out with eligible medical student and staff volunteers. Vaccines were prepared in M RC-5 cells and formalin-inactivated. Three monthly injections of 1 ml in the deltoid muscle were given. Group A received the CLF strain at a dose of 360 ELISA units (El.U) in 0.5 mg aluminium hydroxide (n = 35). The other groups received the HM175 strain as follows: 180 El.U in 1 mg aluminium hydroxide (to group B, n = 42), 360 El.U in 0.5 mg aluminium hydroxide (to group C, n = 40), 360 El.U in 1 mg aluminium hydroxide (to group D, n = 39) and 720 El.U in 1 mg aluminium hydroxide (to group E, n = 43). The geometric mean anti-HAV concentration (GMC) measured in mIV/ml by an ELISA method one month after each injection were: group A, 223, 480, 1635; group B, 123, 221, 649; group C, 185, 365, 1085; group D, 144, 323, 1076; group E, 229, 646, 2521. At month 6, the GMC had fallen by approximately 20%. Seroconversion as measured by ELISA was 100% in groups A and E after one injection, and 100% in all groups after three injections; after two injections, only one subject in group C was still negative. The dose effect with HM175 vaccine was significant. There was a good correlation between ELISA and neutralization (radioimmunofocus inhibition test) titres. One month after the second dose, all subjects in groups A and E had both hepatitis A virus immunoglobulin M (HAV IgM) geometric mean titre, (GMT > 5000) and IgG (GMT > 25,000) as measured by a sensitive terminal dilution ELISA.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335638     DOI: 10.1016/0264-410x(92)90561-w

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

Review 2.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

Review 3.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

Review 4.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 5.  Minimum Infective Dose of the Major Human Respiratory and Enteric Viruses Transmitted Through Food and the Environment.

Authors:  Saber Yezli; Jonathan A Otter
Journal:  Food Environ Virol       Date:  2011-03-16       Impact factor: 2.778

Review 6.  Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data.

Authors:  E Vidor; R Dumas; V Porteret; F Bailleux; K Veitch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

Review 7.  The Xs and Y of immune responses to viral vaccines.

Authors:  Sabra L Klein; Anne Jedlicka; Andrew Pekosz
Journal:  Lancet Infect Dis       Date:  2010-05       Impact factor: 71.421

8.  Impact of Obesity and Being Overweight on the Immunogenicity to Live Attenuated Hepatitis A Vaccine in Children and Young Adults.

Authors:  Termpong Dumrisilp; Jongkonnee Wongpiyabovorn; Supranee Buranapraditkun; Chomchanat Tubjaroen; Nataruks Chaijitraruch; Sittichoke Prachuapthunyachart; Palittiya Sintusek; Voranush Chongsrisawat
Journal:  Vaccines (Basel)       Date:  2021-02-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.